86 related articles for article (PubMed ID: 12626125)
1. Redox control on the cell surface: implications for HIV-1 entry.
Matthias LJ; Hogg PJ
Antioxid Redox Signal; 2003 Feb; 5(1):133-8. PubMed ID: 12626125
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120.
Reiser K; François KO; Schols D; Bergman T; Jörnvall H; Balzarini J; Karlsson A; Lundberg M
Int J Biochem Cell Biol; 2012 Mar; 44(3):556-62. PubMed ID: 22230366
[TBL] [Abstract][Full Text] [Related]
3. Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin.
Azimi I; Matthias LJ; Center RJ; Wong JW; Hogg PJ
J Biol Chem; 2010 Dec; 285(51):40072-80. PubMed ID: 20943653
[TBL] [Abstract][Full Text] [Related]
4. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication.
Auwerx J; Isacsson O; Söderlund J; Balzarini J; Johansson M; Lundberg M
Int J Biochem Cell Biol; 2009 Jun; 41(6):1269-75. PubMed ID: 19038358
[TBL] [Abstract][Full Text] [Related]
5. Redox exchange of the disulfides of human two-domain CD4 regulates the conformational dynamics of each domain, providing insight into its mechanisms of control.
Owen GR; Le D; Stoychev S; Cerutti NM; Papathanasopoulos M
Biochem Biophys Res Commun; 2018 Mar; 497(2):811-817. PubMed ID: 29470989
[TBL] [Abstract][Full Text] [Related]
6. Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.
Cerutti N; Killick M; Jugnarain V; Papathanasopoulos M; Capovilla A
J Biol Chem; 2014 Apr; 289(15):10455-10465. PubMed ID: 24550395
[TBL] [Abstract][Full Text] [Related]
7. Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion.
Barbouche R; Miquelis R; Jones IM; Fenouillet E
J Biol Chem; 2003 Jan; 278(5):3131-6. PubMed ID: 12218052
[TBL] [Abstract][Full Text] [Related]
8. Human CD4 Metastability Is a Function of the Allosteric Disulfide Bond in Domain 2.
Owen GR; Channell JA; Forsyth VT; Haertlein M; Mitchell EP; Capovilla A; Papathanasopoulos M; Cerutti NM
Biochemistry; 2016 Apr; 55(15):2227-37. PubMed ID: 27009680
[TBL] [Abstract][Full Text] [Related]
9. Progress in targeting HIV-1 entry.
Ryser HJ; Flückiger R
Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
[TBL] [Abstract][Full Text] [Related]
10. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1.
Matthias LJ; Yam PT; Jiang XM; Vandegraaff N; Li P; Poumbourios P; Donoghue N; Hogg PJ
Nat Immunol; 2002 Aug; 3(8):727-32. PubMed ID: 12089508
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
Maerz AL; Drummer HE; Wilson KA; Poumbourios P
J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells.
Lundberg M; Mattsson Å; Reiser K; Holmgren A; Curbo S
Sci Rep; 2019 Apr; 9(1):5656. PubMed ID: 30948772
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry.
Gallina A; Hanley TM; Mandel R; Trahey M; Broder CC; Viglianti GA; Ryser HJ
J Biol Chem; 2002 Dec; 277(52):50579-88. PubMed ID: 12218051
[TBL] [Abstract][Full Text] [Related]
14. Snapshot of the interaction between HIV envelope glycoprotein 120 and protein disulfide isomerase.
Wang Z; Zhou Z; Guo ZY; Chi CW
Acta Biochim Biophys Sin (Shanghai); 2010 May; 42(5):358-62. PubMed ID: 20458450
[TBL] [Abstract][Full Text] [Related]
15. Disulfide bonds as switches for protein function.
Hogg PJ
Trends Biochem Sci; 2003 Apr; 28(4):210-4. PubMed ID: 12713905
[TBL] [Abstract][Full Text] [Related]
16. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
17. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
18. Thioredoxin (Trx1) regulates CD4 membrane domain localization and is required for efficient CD4-dependent HIV-1 entry.
Moolla N; Killick M; Papathanasopoulos M; Capovilla A
Biochim Biophys Acta; 2016 Sep; 1860(9):1854-63. PubMed ID: 27233453
[TBL] [Abstract][Full Text] [Related]
19. CD4 activation of HIV fusion.
Sattentau QJ
Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking studies of dithionitrobenzoic acid and its related compounds to protein disulfide isomerase: computational screening of inhibitors to HIV-1 entry.
Gowthaman U; Jayakanthan M; Sundar D
BMC Bioinformatics; 2008 Dec; 9 Suppl 12(Suppl 12):S14. PubMed ID: 19091013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
